“We use cookies on this website to enhance your user experience and to personalise content. By clicking any link or continuing to use our Website you agree to our cookies as per our Privacy Policy. Read More” Ok, I agree

Alprostadil (Caverject)

Trade Name : Caverject

Pharmacia and Upjohn Company LLC

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

Strength 20.5 ug/mL

ALPROSTADIL Genitourinary Arterial Vasodilation [PE],Prostaglandin Analog [EPC],Prostaglandin E1 Agonist [EPC],Prostaglandin Receptor Agonists [MoA],Prostaglandins [CS],Venous Vasodilation [PE]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Alprostadil (Caverject) which is also known as Caverject and Manufactured by Pharmacia and Upjohn Company LLC. It is available in strength of 20.5 ug/mL per ml. Read more

Alprostadil (Caverject) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • CAVERJECT is a prostaglandin E1 agonist indicated
  • For the treatment of erectile dysfunction ().
  • As an adjunct to other diagnostic tests in the diagnosis of erectile dysfunction ().
  • No data
  • Determine the most suitable dose and formulation of CAVERJECT to use. Use a new vial for each dose of CAVERJECT ().
  • Administer first intracavernosal injections in the physician's office and titrate the dose for each patient to the lowest effective dose ().
  • Instruct the patient on proper use and assess that they are well trained in the self-injection technique prior to initiation of at-home use ().
  • Recommended dosage for erectile dysfunction ():n
  • Follow dose titration procedures for each type of erectile dysfunction and determine the maintenance dosage for erectile dysfunction for patient home use in the physician's office ().
  • The recommended frequency of injection is no more than 3 times weekly, with at least 24 hours between each dose ().
  • While on self-injection treatment, the patient should visit the prescribing physician's office every 3 months to assess the efficacy and safety of the therapy ().
  • Follow the procedure for CAVERJECT syringe preparation ().
  • Follow procedure for CAVERJECT intracavernosal injection administration ().
  • To diagnose erectile dysfunction (pharmacologic testing), inject CAVERJECT intracavernosally and monitor patients for the occurrence of an erection ().
  • For injection: 20 mcg and 40 mcg lyophilized powder in single-dose vials for reconstitution.
  • For injection: 20mcg and 40mcg lyophilized powder in single-dose vials for reconstitution ().
  • CAVERJECT is contraindicated:
  • Men who have known hypersensitivity to the drug ().
  • Men who have conditions that predispose them to priapism, such as sickle cell anemia or sickle cell trait, multiple myeloma, or leukemia ().
  • Treatment of erectile dysfunction in men with fibrotic conditions of the penis, such as anatomical deformation, angulation, cavernosal fibrosis, or Peyronie's disease ().
  • Men with penile implants ().
  • No data
  • Prolonged erection and priapism
  • Penile fibrosis
  • Hypotension:
  • Injection site bleeding
  • Cardiovascular risk related to underlying medical conditions:
  • Risks of use in combination with other vasoactive medications injected intracavernosally:
  • Needle breakage:
  • Benzyl alcohol:
  • Counseling patients about sexually transmitted diseases:
  • The following are described elsewhere in the labeling:
  • The most common (u226510%) adverse reaction is penile pain ().
  • To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at (1-800-438-1985 and ) or FDA at 1-800-FDA-1088 or .
  • The potential for pharmacokinetic drug-drug interactions between alprostadil and other agents administered orally or intracavernosally has not been formally studied .
  • No data
  • Overdosage was not observed in clinical trials with CAVERJECT. If intracavernous overdose of CAVERJECT occurs, the patient should be under medical supervision until any systemic effects have resolved and/or until penile detumescence has occurred. Treatment of any systemic symptoms (e.g., hypotension) would be appropriate.
  • CAVERJECT contains alprostadil a synthetic form of prostaglandin E (PGE) and is designated chemically as (11u03b1,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid. The molecular weight is 354.49.
  • Alprostadil is a white to off-white crystalline powder with a melting point between 115u00b0C and 116u00b0 C. CAVERJECT is available as a sterile freeze-dried powder for intracavernosal use in sizes: 20 mcg and 40 mcg per vial. When reconstituted as directed with 1 mL of bacteriostatic water for injection preserved with benzyl alcohol 0.945% w/v, gives 1.13 mL of reconstituted solution. Each mL of CAVERJECT contains 20.5 mcg or 41.1 mcg of alprostadil depending on vial strength, 172 mg of lactose, 47 mcg of sodium citrate and 8.4 mg of benzyl alcohol. The deliverable amount of alprostadil is 20 mcg or 40 mcg per mL because approximately 0.5 mcg for the 20 mcg strength and 1.1 mcg for the 40 mcg strength is lost due to adsorption to the vial and syringe. During manufacture, the pH of alprostadil for injection was adjusted with hydrochloric acid and/or sodium hydroxide before lyophilization.
  • The structural formula of alprostadil is represented below:
  • No data
  • No data
  • The efficacy of CAVERJECT was investigated in men with a diagnosis of erectile dysfunction due to psychogenic, vasculogenic, neurogenic, and/or mixed etiology in two double-blind placebo controlled studies (Study 1 and Study 2) and in one 6-month open-label study (Study 3). In clinical studies (Study 1 and Study 3), over 80% of patients experienced an erection sufficient for sexual intercourse after intracavernosal injection of CAVERJECT.
  • CAVERJECT is a lyophilized powder supplied in vials containing 23.2 or 46.4 mcg of alprostadil for intracavernosal administration. When reconstituted as directed with 1 milliliter of bacteriostatic water for injection preserved with benzyl alcohol 0.945% w/v, the delivered amount of alprostadil is 20 mcg or 40 mcg.
  • Store CAVERJECT 20 mcg vials between 20u00b0C to 25u00b0C (68u00b0F to 77u00b0F). The reconstituted solution should be used within 24 hours when stored at or below 25u00b0C (77u00b0F) and not refrigerated or frozen.
  • Store CAVERJECT 40 mcg vials between 2u00b0C to 8u00b0C (36u00b0 to 46u00b0F) until dispensed. Once dispensed, vials should be stored at or below 25u00b0C (77u00b0F) for up to 3 months or until the expiration date, whichever occurs first. The reconstituted solution should be used within 24 hours when stored at or below 25u00b0C (77u00b0F) and not refrigerated or frozen.
  • When reconstituted and used as directed, the deliverable amount of alprostadil is 20 micrograms or 40 micrograms, respectively. Only bacteriostatic water for injection preserved with benzyl alcohol 0.945% w/v, should be used when reconstituting CAVERJECT.
  • CAVERJECT is available in the following packages:
  • The following supplies are needed for injection and are not supplied with CAVERJECT:
  • Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
  • LAB-0764-3.0
  • CAVERJECT [KAV-er-jeckt]n (alprostadil)for injection, for intracavernosal use
  • Read this Patient Information before you start using CAVERJECT and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
  • What is CAVERJECT?
  • CAVERJECT is a prescription medicine used:
  • CAVERJECT is not meant for use in women or children.
  • Do not use CAVERJECT if you:
  • Before you use CAVERJECT, tell your healthcare provider about all your other medical conditions, especially if you:
  • Tell your healthcare provider about all the medicines you take,
  • CAVERJECT may affect the way other medicines work, and other medicines may affect the way CAVERJECT works causing side effects.
  • Especially tell your healthcare provider if you take
  • Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure.
  • Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.
  • How should I use CAVERJECT?
  • You should see your healthcare provider every 3 months for check-ups to be sure that CAVERJECT is working the right way and to change your CAVERJECT dose if needed.
  • What are the possible side effects of CAVERJECT?
  • CAVERJECT may cause serious side effects, including:
  • CAVERJECT does not protect you or your partner from getting sexually transmitted infections
  • The most common side effect of CAVERJECT is
  • These are not all the possible side effects of CAVERJECT.
  • Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
  • General information about the safe and effective use of CAVERJECT
  • Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not use CAVERJECT for a condition for which it was not prescribed. Do not give CAVERJECT to other people even if they have the same symptoms that you have. It may harm them.
  • You can ask your pharmacist or healthcare provider for information about CAVERJECT that is written for health professionals.
  • What are the Ingredients in CAVERJECT?
  • Active ingredient:
  • Inactive ingredients:
  • LAB-1045-1.0
  • Revised: December 2017
  • CAVERJECT [KAV-er-jeckt]u00ae(alprostadil) for injection, for intracavernosal use
  • Your healthcare provider should show you how to prepare and inject CAVERJECT the right way before you inject it for the first time. Do not
  • Information about how to safely inject CAVERJECT:
  • CAVERJECT comes in 20 mcg or 40 mcg strengths. n
  • Prepare the Syringe
  • After your injection:
  • Dispose of your used CAVERJECT syringe and needles.
  • How should I store CAVERJECT?
  • CAVERJECT 20 mcg vial storage information
  • CAVERJECT 40 mcg vial storage information
  • Keep CAVERJECT and all medicines out of the reach of children.
  • This Patient Information and Instructions for Use has been approved by the U.S Food and Drug Administration.
  • LAB-0009-6.0
  • Revised December 2017
  • NDC 0009-3701-08
  • Pfizer
  • Caverjectn
  • 20 mcg
  • For Intracavernosal Use Only
  • Single Dose Vial n n
  • NDC 0009-3701-05Contains 6 of NDC 0009-3701-08
  • Pfizern- Caverjectn
  • alprostadil forinjection
  • For Intracavernosal Use Only
  • 6 Single-Dose Vials
  • 20 mcg
  • Diluent to be used with this product shouldcontain benzyl alcohol as a preservative.
  • This Package Does NOT Contain Diluentn n
  • NDC 0009-7686-01
  • Pfizer
  • Caverjectn
  • 40 mcg
  • For Intracavernosal Use Only
  • Single Dose Vialn n
  • NDC 0009-7686-04Contains 6 of NDC 0009-7686-01
  • Pfizern- Caverjectn
  • alprostadil forinjection
  • For Intracavernosal Use Only
  • 6 Single-Dose Vials
  • 40 mcg
  • Diluent to be used with this product shouldcontain benzyl alcohol as a preservative.
  • This Package Does NOT Contain Diluentn n

Similar Products

Desogestrel And Ethinyl Estradiol (Emoquette)

Desogestrel And Ethinyl Estradiol (Emoquette)

Manufacturer: REMEDYREPACK INC.

Presentation: KIT

Strength:

Pack Size:

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Diphenoxylate Hydrochloride And Atropine Sulfate (Diphenoxylate Hydrochloride And Atropine Sulfate)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET

Strength: 2.5; .025 mg/1; mg/1

Pack Size:

Fluoxetine Hydrochloride (Fluoxetine)

Fluoxetine Hydrochloride (Fluoxetine)

Manufacturer: REMEDYREPACK INC.

Presentation: CAPSULE

Strength: 40 mg/1

Pack Size:

Metoprolol Succinate (Metoprolol Succinate)

Metoprolol Succinate (Metoprolol Succinate)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET, EXTENDED RELEASE

Strength: 25 mg/1

Pack Size:

Losartan Potassium (Losartan Potassium)

Losartan Potassium (Losartan Potassium)

Manufacturer: REMEDYREPACK INC.

Presentation: TABLET, FILM COATED

Strength: 25 mg/1

Pack Size:

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71245 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Get Price

Are you an existing customer or a vendor of GNH India? Log in here to

View your Transaction
COMPANY
SERVICES
QUICK LINKS
CONTACT US
Registered Office Address:

Unit # G- 14, 15, 16, 17, Ground Floor, Prabhadevi Industrial Estate, Enterprises Industrial Premises, 408, Veer Sawarkar Road, Prabhadevi,
Mumbai 400025 India

US Office Address:

GNH Pharmaceuticals USA LLC,
Suite E # 499, 1235 EAST BLVD,
Charlotte, NC, 28203, U.S.A
TEL: +1 704 557 0412

Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.